Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.

[1]  G. Lyman,et al.  Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. , 2019, Thrombosis research.

[2]  G. Raskob,et al.  Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study , 2018, Thrombosis and Haemostasis.

[3]  G. Lyman,et al.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer‐Associated Venous Thromboembolism , 2017, The New England journal of medicine.

[5]  S. Noble,et al.  Factors influencing adherence to clinical guidelines in the management of cancer‐associated thrombosis , 2016, Journal of thrombosis and haemostasis : JTH.

[6]  K. Hood,et al.  Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Khorana,et al.  Evaluation of US prescription patterns: Are treatment guidelines for cancer-associated venous thromboembolism being followed? , 2016, Thrombosis research.

[8]  S. Goldhaber,et al.  Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study , 2015, Hospital practice.

[9]  Catch Investigators.  Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: A randomized clinical trial , 2015 .

[10]  K. Bailey,et al.  Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. , 2014, Blood.

[11]  D. Coyle,et al.  Estimating quality of life in acute venous thrombosis. , 2013, JAMA internal medicine.

[12]  C. Flowers,et al.  Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Kakkar.  Venous thromboembolism prophylaxis and treatment in patients with cancer. , 2008, Clinical advances in hematology & oncology : H&O.

[14]  P. Bossuyt,et al.  Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences , 2004, Thrombosis and Haemostasis.

[15]  L. Elting,et al.  Outcomes and cost of deep venous thrombosis among patients with cancer. , 2004, Archives of internal medicine.

[16]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[17]  Paolo Prandoni,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[18]  G. Barosi,et al.  Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. , 2001, The American journal of medicine.

[19]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.